BioMedWire Stocks

Study Links Iron Deficiency to Disturbed Sleep Among Autism, ADHD Patients

Sleep disorders are often caused by hypermotor restlessness, restless leg syndrome, hyperarousability, periodic limb movements in sleep and restless sleep disorder. Now, a new study has considered the role iron levels play in causing these disorders.

Iron is usually found in microglia, oligodendrocytes, astrocytes and neurons. This element is needed to help synthesize neurotransmitters that regulate the wake/sleep cycle.

The study used data gathered from structured intake forms and clinical evaluations conducted at the Child & Adolescent Psychiatry division of the Sleep/Wake-Behavior clinic in BC Children’s Hospital. Data on parental history of iron deficiency, recent iron status and covariate factors such as medications and comorbidities was recorded.

The mean age of patients included in the study was 11, with the researchers finding that 188 of the patients fulfilled the criteria for anemic or nonanemic iron deficiency. Several participants also reported a family history of the deficiency, with most of them revealing that their mothers experienced some deficiency during pregnancy and/or in their teenage years.

Additionally, about one-half of the study cohort admitted to suffering from disruptive behaviors, with ADHD being a common diagnosis.

The researchers conducted a retrospective analysis of the data, finding that genetic conditions, neurologic conditions, developmental delay/intellectual disability and autism spectrum disorder were common neurodevelopmental presentations. In their report, they revealed that 11% of the patients suffered from painful restless leg syndrome with another 52% reporting a family history of the same.

In addition, 30% of the patients also lived with periodic limb movements in sleep/restless sleep disorder. The researchers explained that a family history of iron deficiency heightened the likelihood of an individual having restless sleep disorder, insomnia and familial restless leg syndrome. They also highlighted a number of limitations, including the lack of data on the potential causes of iron deficiency.

The study lacked a structured categorization for some data. For instance, no distinction was made between nonanemic and anemic iron deficiency in the e-intake forms. Further, data on father and mother iron deficiencies weren’t separated.

Future research is required to shed light on the mechanisms involved in iron deficiency, given that this deficit may be caused by different factors, among them inadequate nutrition or inflammation.

The team published its findings in the “Nutrients” journal. The researchers involved include David Wensley, Osman S. Ipsiroglu, Alexandra L. Wagner, Parveer K. Pandher, Anamaria Richardson, Olivia Hill, Marion Suzanne Lewis, Scout McWilliams, Calvin Kuo, Melissa Braschel, Elizabeth Keys, Robin Friedlander and Katherine Edwards.

As companies such as PaxMedica Inc. (OTC: PXMD) continue their efforts to develop treatments targeting autism, it is likely that more insights into the factors behind the onset of the symptoms that patients manifest will become known.

NOTE TO INVESTORS: The latest news and updates relating to PaxMedica Inc. (NASDAQ: PXMD) are available in the company’s newsroom at https://ibn.fm/PXMD

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

Systemic Challenges in US Health Care Push Cancer Patients to Fly to China

For decades, lots of American patients have been traveling to “fringe” countries like Turkey, Cuba…

1 day ago

VERAXA Biotech AG (NASDAQ: VRXA) Building a New Approach to Precision Cancer Therapy

VERAXA is developing antibody-based cancer therapies aimed at improving the therapeutic window of existing treatment…

1 day ago

Earth Science Tech Inc.’s (ETST) Shareholders Approve Key Proposals in Annual Meeting

Earth Science Tech held its first annual meeting of stockholders, virtually, on August 31, 2026+…

2 days ago

Rising Rates of the Uninsured Could Affect Every American

As more Americans become underinsured or uninsured as a result of rising health insurance premiums and the several…

5 days ago

Regentis Biomaterials Ltd. (NYSE American: RGNT) Advances GelrinC as a Potential New Approach to Knee Cartilage Repair

Researchers across the field, from Duke University to Mayo Clinic, are increasingly focused on restoring…

5 days ago

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

BioMedWire Editorial Coverage: Today's multiple sclerosis treatments can slow down disease progression, but none of them…

6 days ago